Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>Products>This Product

Biopharmaceutical Manufacturing

Product Image
Product Description

Process development, custom manufacturing and innovative purification systems.

We offer you a unique combination of services and advanced technologies for purifying your biopharmaceuticals, from laboratory to industrial scale:

• Bioprocess development: upstream and downstream processing, fill & finish
• Outsourcing solutions: contract manufacturing services, from master cell bank to the commercial released drug product, aseptic formulation and fill & finish
• Insourcing solutions: chromatography and membrane filtration technologies, from lab to industrial scale

Solutions for Biologics Manufacturing

Shorten Time-to-Market:

The biopharmaceutical industry’s objective is to bring new biomolecules to clinical trial more quickly and, therefore, reduce time-to-market. Our process expertise enables us to reduce upstream and downstream bioprocessing development lead-times using advanced methodologies, including where applicable proprietary computer modeling tools.

Regulatory Compliance:
The biopharmaceutical industry cannot compromise when it comes to quality and patient safety. Our solutions comply with all regulatory and quality requirements. Our solutions ensure the highest quality and safety levels while optimizing purity and yield, adhering to the FDA PAT (Process Analytical Technologies) guidelines.

We have built and run our own bioproduction facilities and can bring pragmatic expertise to all disciplines including facility design, process design and development, as well as regulatory and quality requirements.

Increased Production Capacities:
With higher titres, tougher competition and increasingly stringent quality and regulatory requirements, the challenge is to align the efficiency of downstream processing to upstream titres. Our batch and continuous DSP solutions offer unique features that help develop the optimum bioprocess to match your upstream process performance.

Solutions Toward Lean Manufacturing
At Novasep , we can provide solutions for the lean manufacturing of your biopharmaceutical. Through innovative and unique products, all components of lean manufacturing are observed! Interested to learn more, please click here!

Offering for Biopharmaceutical Production and Purification

Types of biologics produced with Novasep services

We provide bioprocess development and contract manufacturing services for most types of biologics, from pre-clinical supply to commercial manufacturing.

We combine the complementary talents of chemical and process engineers as well as chemists and biologists to offer our expertise in custom manufacturing services to meet your expectations.  We can produce your development cell bank with several types of cell lines (see upstream biomanufacturing services). We can develop and optimize your cell line  as well as produce your biologics from clinical batches for clinical trials up to phase III with our contract biomanufacturing services.

We provide formulation and fill & finish services to offer a complete solution for your biologics production as well as complete logistic management.

We own a unique palette of DSP technologies (preparative LPLC, MPLC, HPLC, SMCC, filtration solutions) developed for biologics manufacturing.

We provide in-sourcing solutions including innovative and user-friendly biochromatography solutions (Prochrom® Biochromatography columns and Prochrom® Hipersep low pressure chromatography equipment, silica-based protein A media and Prochrom® BioSC multicolumn chromatography systems) and Tangential Flow Filtration (TFF) solutions (TangenX polymeric membranes and Kerasep® Bio mineral membranes, reusable and Sius™ single-use cassettes, TFF systems) for biologics manufacturing.

Product Biopharmaceutical Manufacturing
Company Novasep Inc
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Novasep Inc
82, Boulevard de la Moselle Site Eiffel BP 50 54340 Pompey FRANCE

Tel: + 33 383 49 71 30
Fax: + 33 383 49 71 49

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down


Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos